Tireilizumab（PD-1 inhibitor）
PreclinicalSmall molecule
Tireilizumab（PD-1 inhibitor） is one of 49 small molecule programs targeting Colorectal Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Fudr
PfizerPhase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Tecentriq
RochePhase 3
Decadron
AAspen Global Incorporated
Phase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
5-Fu
TToray Industries, Inc
Phase 3
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Calcium Levofolinate
FFujian Cancer Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYunnan Cancer Hospital